Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION

NCT03281304 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT03281304
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03281304 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PHASE 3B/4, MULTI-CENTER, DOUBLE-BLIND, RANDOMIZED, PARALLEL GROUP STUDY OF TOFACITINIB (CP-690,550) IN SUBJECTS WITH ULCERATIVE COLITIS IN STABLE REMISSION
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Terminated
Start date
November 16, 2017
Completion date
March 18, 2022
Enrollment
140 (actual)
Sites
80

Conditions

As the registry lists them; a condition with its own page is linked.

ulcerative colitis